Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating a fixed budget, and that it would introduce inequities based on individual productivity or income. We argue that patient and carer time are vital inputs to healthcare, and that ignoring them reduces rather than improves both efficiency and fairness.
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
Seven reflections on the UK EQ-5D-5L value set – and what comes next
30 March 2026
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its adoption by NICE is set to shape how health-related quality of life is valued, raising important questions for future HTA decisions.
Why do we expect obesity medicines to work differently?
5 March 2026
Weight regain after stopping GLP-1 medicines isn’t a treatment failure — it shows that obesity is a chronic, relapsing condition. Like other long-term therapies, benefits last only while treatment continues. Reframing obesity this way can improve outcomes and reduce stigma.
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
Understanding the preferences of people with acute leukemia for different health outcomes
25 September 2025
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wanted to understand which aspects, or “dimensions”, of health-related quality-of-life are most important to the general public and to persons with acute leukemia.
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
OHE’s written submission to parliament focused on raising population health in older age and increasing access to fertility treatments as two possible avenues to address the challenges of demographic change.
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…